New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer’s Pathobiology
Exploring GLP-1 drugs as preventive therapy may still hold promise within broader strategy targeting Alzheimer’s pathways beyond amyloid, ADDF notes SAN DIEGO, Dec. 4, 2025 /PRNewswire/ — Today, Novo Nordisk presented new topline results from […]
